



iPS細胞由来 人工血小板製剤 想定エコシステム

～社会実装に必要な事業要素～




人工血小板製剤 出口戦略シナリオ



有事に備えた止血製剤製造技術の開発・実証

ほぼ全ての患者に輸血可能なiPS細胞由来人工血小板の実用化




高品質人工血小板の連続製造システムの研究開発と実用化

次世代型人工血小板の実装




「有事に備えた止血製剤製造技術の開発・実証」プログラム
 研究推進法人(FA): 国立研究開発法人新エネルギー・産業技術総合開発機構(NEDO)

The Universal iPS Cell-Derived Platelets Expected Ecosystem: Business Elements Necessary for Social Implementation




The Universal iPS Cell-Derived Platelets : Exit Strategy




Demonstration of Robust Hemostatic Production Systems for Critical Situations

Clinical Implementation of iPSC-Derived Artificial Platelets Transfusable to Nearly All Patients



R&D and Commercialization of Continuous Manufacturing Technology for High-Grade Artificial Platelets

Implementation of Next-Generation Artificial Platelets



"Development and Demonstration of Hemostatic Agent Manufacturing Technologies for Emergency Preparedness"
Program Funding Agency: New Energy and Industrial Technology Development Organization (NEDO)